# Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial

> **NCT04624256** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 208 (actual)

## Conditions studied

- Prostate Adenocarcinoma
- Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
- Stage II Prostate Cancer AJCC v8
- Stage IIA Prostate Cancer AJCC v8
- Stage IIB Prostate Cancer AJCC v8
- Stage IIC Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** Discussion
- **RADIATION:** Hypofractionated Radiation Therapy
- **RADIATION:** Hypofractionated Radiation Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT04624256
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-10
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04624256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04624256, "Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04624256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*